Glycinemax Fermented by a Novel Probiotic, Bifidobacterium animalis subsp. lactis LDTM 8102, Increases Immuno-Modulatory Function

Jae Hwan Kim, Minju Jeong, Eun Hee Doo, Young Tae Koo, Seon Joo Lee, Ji Won Jang, Jung Han Yoon Park, Chul Sung Huh, Sanguine Byun, Ki Won Lee

Research output: Contribution to journalArticlepeer-review


Many probiotic species have been used as a fermentation starter for manufacturing functional food materials. We have isolated Bifidobacterium animalis subsp. lactis LDTM 8102 from the feces of infants as a novel strain for fermentation. While Glycine max has been known to display various bioactivities including anti-oxidant, anti-skin aging, and anti-cancer effects, the immune-modulatory effect of Glycine max has not been reported. In the current study, we have discovered that the extract of Glycine max fermented with B. animalis subsp. lactis LDTM 8102 (GFB 8102), could exert immuno-modulatory properties. GFB 8102 treatment increased the production of immune-stimulatory cytokines in RAW264.7 macrophages without any noticeable cytotoxicity. Analysis of the molecular mechanism revealed that GFB 8102 could upregulate MAPK2K and MAPK signaling pathways including ERK, p38, and JNK. GFB 8102 also increased the proliferation rate of splenocytes isolated from mice. In an animal study, administration of GFB 8102 partially recovered cyclophosphamide-mediated reduction in thymus and spleen weight. Moreover, splenocytes from the GFB 8102-treated group exhibited increased TNF-α, IL-6, and IL-1β production. Based on these findings, GFB 8102 could be a promising functional food material for enhancing immune function.

Original languageEnglish
Pages (from-to)1146-1153
Number of pages8
JournalJournal of microbiology and biotechnology
Issue number9
Publication statusPublished - 2022 Sept 28

Bibliographical note

Funding Information:
This project was supported by the Kwangdong Pharm Co. Ltd. This work was also supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science, ICT & Future Planning)[No. 2018R1A2A1A05078707 and 2020R1A2C1010703]. Young Tae Koo, Seon Joo Lee and Ji Won Jang are employed by the Kwangdong Pharm Co. Ltd, and they along with the other authors, declare no conflict of interest. Graphical abstract is created with

Publisher Copyright:
© 2022 Korean Society for Microbiology and Biotechnology. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Applied Microbiology and Biotechnology


Dive into the research topics of 'Glycinemax Fermented by a Novel Probiotic, Bifidobacterium animalis subsp. lactis LDTM 8102, Increases Immuno-Modulatory Function'. Together they form a unique fingerprint.

Cite this